Notably, a cohort of cholangiocarcinoma patients demonstrated enhanced therapeutic outcomes following treatment with a composite of CAR T-cells specific to epidermal growth factor receptor (EGFR) and CD133 [121]. The gene discussed is EGFR; the disease is cholangiocarcinoma.